A
Andrew A. Renshaw
Researcher at Baptist Memorial Hospital-Memphis
Publications - 267
Citations - 18527
Andrew A. Renshaw is an academic researcher from Baptist Memorial Hospital-Memphis. The author has contributed to research in topics: Prostate cancer & Prostate-specific antigen. The author has an hindex of 53, co-authored 263 publications receiving 17540 citations. Previous affiliations of Andrew A. Renshaw include Hospital of the University of Pennsylvania & University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
Biochemical Outcome after radical prostatectomy, external beam Radiation Therapy, or interstitial Radiation therapy for clinically localized prostate cancer
Anthony V. D'Amico,R. Whittington,S.B. Malkowicz,Daniel Schultz,Kenneth R. Blank,Gregory A. Broderick,John E. Tomaszewski,Andrew A. Renshaw,Irving D. Kaplan,Clair J. Beard,Alan J. Wein +10 more
TL;DR: Low-risk patients had estimates of 5-year PSA outcome after treatment with RP, RT, or implant with or without neoadjuvant androgen deprivation that were not statistically different, whereas intermediate- and high- risk patients treated with RP or RT did better then those treated by implant.
Journal ArticleDOI
Gene expression correlates of clinical prostate cancer behavior.
Dinesh Singh,Phillip G. Febbo,Phillip G. Febbo,Kenneth N. Ross,Donald G. Jackson,Judith Manola,Christine Ladd,Pablo Tamayo,Andrew A. Renshaw,Anthony V. D'Amico,Jerome P. Richie,Eric S. Lander,Massimo Loda,Philip W. Kantoff,Todd R. Golub,William R. Sellers +15 more
TL;DR: The results support the notion that the clinical behavior of prostate cancer is linked to underlying gene expression differences that are detectable at the time of diagnosis.
Journal ArticleDOI
Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer
Anthony V. D'Amico,R. Whittington,S.B. Malkowicz,Daniel Schultz,Kenneth R. Blank,Gregory A. Broderick,John E. Tomaszewski,Andrew A. Renshaw,Irving D. Kaplan,Clair J. Beard,Alan J. Wein +10 more
TL;DR: Low-risk patients had estimates of 5-year PSA outcome after treatment with RP, RT, or implant with or without neoadjuvant androgen deprivation that were not statistically different, whereas intermediate- and high- risk patients treated with RP or RT did better then those treated by implant.
Journal ArticleDOI
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Anthony V. D'Amico,Judith Manola,Marian Loffredo,Andrew A. Renshaw,Alyssa DellaCroce,Philip W. Kantoff +5 more
TL;DR: In this paper, the authors evaluated the benefit of 3D conformal radiation therapy (3D-CRT) alone or in combination with 6 months of androgen suppression therapy (AST) in patients with clinically localized prostate cancer.
Journal ArticleDOI
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
TL;DR: The addition of 6 months of AST to RT resulted in increased overall survival in men with localized but unfavorable-risk prostate cancer, and this result may pertain only to men without moderate or severe comorbidity.